Media Coverage
Selected media coverage of Vesper Biotechnologies.
Features Rogério Vivaldi, Chairman of Vesper Bio, discussing the company's 8 deep techs in health and sustainable agtech, along with Vesper's presence at the SC Day in New York during Brazil Week.
Read ArticleHighlights Vesper's R$ 75 million funding round aimed at bridging academic research and commercialization, operating from its 3,000 m² biotech hub in Florianópolis.
Read ArticleCovers the Vesper Annual Meeting 2026 in Florianópolis, detailing CEO Gabriel Bottós' vision of cell-programming technology, national sovereignty, 17 international patents, and a team including 75 PhDs.
Read ArticleInterview conducted during the Vesper meeting in Florianópolis, updating Phase 1 clinical trial progress for polylaminin (spinal cord injury therapy).
Read ArticleReports on the opening of the Vesper Annual Meeting 2026 and announces R$ 25 million raised towards its R$ 75 million target, backed by investors like the Lafer family, Rise Ventures, and ACNext.
Read ArticleOutlines Vesper's evaluation of over 4,500 scientific projects to build 8 portfolio companies spanning oncology, neurodegenerative diseases, and sustainable agriculture.
Read ArticleCovers the launch of Vesper's latest capital raise to scale acquisitions and deep-tech portfolio developments.
Read ArticleDiscusses Vesper's model for guiding PhD researchers into successful founders, collaborating with leading scientists like Mayana Zatz.
Read ArticleDetails the launch and growth of Vesper Bio Labs in Florianópolis, housing key portfolio startups like Symbiomics, InEdita Bio, Aptah, and Reddot Bio.
Read ArticleIn-depth profile on how founders Gabriel and Rafael Bottós operate as 'co-pilots' for researchers to transform Brazilian intellectual property into global companies.
Read Article